David Berry is a general partner with venture capital firm Flagship Pioneering. In recent years, he has co-founded companies that are developing microbiome products for both human therapeutics and agricultural applications. He spoke with Xconomy during Biotech Week Boston in September about the promise of microbiome medicine and the challenges of developing a new class of drugs.

• Share on Facebook
• Share on Twitter
• LinkedIn
• Email
• Reprints

Trending on Xconomy

• Bankrupt uBiome Says Founders May Have Misled Investors
• With FDA’s Eye on JAK Drugs, Concert Moves One Ahead For Hair Loss
• Vir Bio Plans IPO to Fund Clinical Trials of Infectious Disease Drugs